復星醫藥(02196.HK)第一季度淨利潤6.10億元 同比減少38.22%
格隆匯4月29日丨復星醫藥(02196.HK)發佈公吿,2024年第一季度,集團實現營業收入101.57億元,較上年同期減少6.56%。同比變動主要由於2023年第一季度營業收入中包含捷倍安(阿茲夫定片)等新冠相關產品的貢獻,2024年同期該等產品收入同比大幅下降。
報吿期內,集團實現歸屬於上市公司股東的淨利潤6.10億元,同比減少38.22%;其中,實現歸屬於上市公司股東的扣除非經常性損益的淨利潤6.09億元,同比減少33.81%。主要影響因素:(1)上年同期新冠相關的產品銷售貢獻,2024年該類產品收入大幅下降導致相應的利潤減少;(2)Gland Pharma併購Cenexi的攤銷及Cenexi的運營虧損等影響。報吿期內,本集團非經常性損益為0.01億元,同比減少0.66億元,變動原因主要繫上年同期包含天津藥業等非核心資產出售收益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.